Image credit- dreamstime.com
Japan based Sumitomo Dainippon Pharma Co., Ltd. has announced the appointment of Hiroshi Nomura as Representative Director, President and CEO. Currently, Nomura is serving as the Executive Vice President at the company. The new appointment is effective from 1 April 2018. Nomura is replacing Masayo Tada, who has now been appointed as the Chairman.
The pharma company has been working to realize its Mid-term Business Plan ending in fiscal 2017 and its vision to become a globally active R&D based company, contributing to medical care through leading-edge technologies.
One of the origins of the company is Sumitomo Pharmaceuticals, incorporated in 1984 as a subsidiary of Sumitomo Chemical. Nomura became a part of Sumitomo Pharmaceuticals in 2003. In 2005, he took charge as the Senior Director, Finance & Accounting in Sumitomo Dainippon Pharma.
Since then, Nomura has been leading different roles and responsibilities in the company. In 2010, Sunovion (formerly Sepracor Inc.), was acquired by Sumitomo Dainippon. Nomura took the position of the Vice Chair, Executive Vice President and CFO, Sunovion Pharmaceuticals Inc. in 2012. Following 2014, he became associated with the Regenerative & Cellular Medicine Office, at Sumitomo Dainippon Pharma.
